Q1 Earnings Forecast for BrainsWay Issued By Northland Capmk

BrainsWay Ltd. (NASDAQ:BWAY) – Analysts at Northland Capmk decreased their Q1 2025 earnings per share (EPS) estimates for BrainsWay in a research note issued on Tuesday, March 11th. Northland Capmk analyst C. Byrnes now forecasts that the company will earn $0.01 per share for the quarter, down from their prior estimate of $0.02. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share. Northland Capmk also issued estimates for BrainsWay’s Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at $0.15 EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of BrainsWay in a report on Wednesday.

BrainsWay Price Performance

BrainsWay stock opened at $10.21 on Friday. The business has a fifty day moving average price of $10.26 and a 200-day moving average price of $9.61. BrainsWay has a 1-year low of $4.61 and a 1-year high of $11.79. The stock has a market capitalization of $192.22 million, a price-to-earnings ratio of 102.11 and a beta of 1.29.

Institutional Trading of BrainsWay

A number of institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP boosted its stake in BrainsWay by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after purchasing an additional 1,786 shares in the last quarter. Rhumbline Advisers boosted its stake in BrainsWay by 10.8% in the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after purchasing an additional 2,144 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in BrainsWay by 14.6% in the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after purchasing an additional 2,446 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in BrainsWay in the 4th quarter worth approximately $44,000. Finally, JPMorgan Chase & Co. boosted its stake in BrainsWay by 61.9% in the 4th quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company’s stock worth $226,000 after purchasing an additional 9,149 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors and hedge funds.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.